<DOC>
	<DOCNO>NCT00594217</DOCNO>
	<brief_summary>The rapidity progesterone ( P ) suppress daytime lutenizing hormone ( LH ) ( inference gonadotropin release hormone ( GnRH ) ) pulse frequency unknown . We propose assess use randomize , cross-over , placebo-controlled study . Ovulatory woman begin E2 patch day 4-8 cycle , woman PCOS begin E2 patch either day 4-8 cycle least 8 week post-menses . After 3 E2 administration , woman undergo 24-h sampling study GCRC . Beginning 2000 h , blood LH , FSH , E2 , P , T obtain 24-h period . After 10 h sampling , either oral micronized P ( 100 mg p.o . ) suspension placebo suspension administer ( accord randomization ) . At completion sampling , E2 patch discontinue . During subsequent menstrual cycle ( least 3 week oligomenorrheic PCOS ) , subject undergo another GCRC study identical first ( include pretreatment E2 ) except oral P exchange placebo vice versa accordance crossover design . We assess acute effect progesterone LH frequency , secondary endpoint mean LH , LH pulse amplitude , mean follicle-stimulating hormone ( FSH ) . We propose two primary hypothesis : ( 1 ) administration P ( 0600 h ) normally cycle adult woman follicular phase result demonstrable suppression daytime LH ( inference GnRH ) pulse frequency within 12 hour ; ( 2 ) administration P ( 0600 h ) woman PCOS result less suppression daytime LH pulse frequency ovulatory woman without PCOS . A secondary hypothesis augmentation LH amplitude P administration less PCOS compare normal control .</brief_summary>
	<brief_title>Determining How Quickly Progesterone Slows LH Pulse Frequency</brief_title>
	<detailed_description>Studies protocol perform normally cycle woman woman PCOS 18 35 year old . Criteria PCOS ( ) clinical and/or biochemical evidence hyperandrogenism , ( b ) oligomenorrhea , ( b ) absence clinical biochemical evidence potential cause hyperandrogenism and/or oligomenorrhea . After informed consent obtain , potential subject undergo screen history physical exam . Subjects need fast minimum 8 hour prior screen blood draw . After informed consent obtain , blood test ( ~ 16 cc ) draw 0800-0900 h follow : LH , FSH , progesterone ( P ) , estradiol ( E2 ) , total testosterone , SHBG , 17-OHP , androstenedione , DHEA-S , beta-hCG , TSH , prolactin , CBC , chemistry liver panel , hemoglobin A1c , fast insulin , fast glucose . Additionally , BOD POD® use measure total fat mass , fat free mass , percent body fat . Waist hip circumference measure . This study follow crossover design , assessment acute effect P placebo ( individually ) GnRH pulse frequency ; subject randomize receive either P placebo first GCRC admission , subsequent GCRC study occur subsequent cycle . Women begin E2 patch ( 0.1 mg/d per patch , 2 patch [ deliver total 0.2 mg/d ] place abdomen change every 2 ) even day 4-8 study cycle ( control PCOS ) &gt; = 8 week post-menses ( PCOS ) . These patch continue total 4 , GCRC admission occur day 3 E2 administration . Exogenous E2 administration standardize hypothalamic exposure E2 help ensure presence sufficient hypothalamic P receptor . Four 5 day schedule GCRC admission , subject come GCRC outpatient blood draw P beta-HCG ( 2 cc ) . If 30 day elapse ( ) recent hemoglobin hematocrit ( b ) schedule GCRC admission , hemoglobin hematocrit also draw time ( 1cc ) . After 3 E2 administration , woman undergo 24-h sampling study GCRC . Estradiol administration ( E2 patch ) continue throughout GCRC admission . Subjects admit GCRC 1800 h ( 2 h prior sample ) . Beginning 2000 h , blood obtain indwell i.v . forearm heparin lock 24-h period follow : LH every 10 min ( 1 ml ) ; P every 30 min ( 1 ml ) ; FSH , E2 , T every 2 h ( assays run sample LH P ) . SHBG , fast insulin , fast glucose ( i.e. , fast since 2200 h ) run 0600 h sample ( extra 2 cc draw ) . ( Subjects fast 2200 0600 h. ) After 10 h sampling ( i.e. , 0600 h ) , either oral micronized P ( 100 mg p.o . ) suspension placebo suspension administer ( accord randomization ) . With exogenous P , aim achieve mean plasma P concentration 4-8 ng/ml . Subjects allow sleep day ( i.e. , 0600 2200 h ) . Subjects encourage sleep 2200 0600 . Sleep formally evaluate ( extraoculograms , electroencephalogram , wrist actigraphy , etc. ) . At completion sampling , E2 patch discontinue . Volunteers discharge oral iron ( 325 mg BID ) . We ask woman eat food provide GCRC . Subjects undergo another GCRC study identical first ( include pretreatment E2 , outpatient blood draw 4-5 day admission , etc . ) , except oral P exchange placebo vice versa accordance crossover design . ( Subjects begin E2 patch even cycle day 4-8 [ control PCOS ] &gt; = 8 week post-menses [ PCOS ] . ) In way , able standardize change GnRH pulse frequency P administration change GnRH pulse frequency placebo administration . The study end second GCRC admission . Subjects ask continue oral iron supplementation least 30 last GCRC admission .</detailed_description>
	<mesh_term>Progesterone</mesh_term>
	<criteria>Subjects healthy woman two group : ( 1 ) woman regular menstrual cycle evidence hyperandrogenism , ( 2 ) woman PCOS ( defined clinical/biochemical evidence hyperandrogenism plus oligomenorrhea , evidence endocrinopathies ) . Subjects 1835 year old . Subjects willing strictly avoid pregnancy ( use nonhormonal method ) time study must willing able provide inform consent . We exclude woman history disorder may potentially complicate hormonal treatment , DVT breast , ovarian , endometrial cancer . We exclude woman cancer diagnosis and/or treatment ( exception basal cell squamous skin carcinoma ) unless remain clinically disease free ( base appropriate surveillance ) five year . Women anemia ( hematocrit &lt; 36 % and/or hemoglobin level &lt; 12 g/dl ) treat iron maximum 2 sequential month 1st admission and/or 2nd admission . If remain anemic 2 sequential month ferrous gluconate ( 325 mg bid ) , exclude participation study . Women history disorder may potentially complicate longterm iron supplementation , hemochromatosis polycythemia vera , exclude . Women significant history cardiac pulmonary dysfunction ( e.g. , know suspect congestive heart failure ; know suspect coronary atherosclerosis ; asthma require systemic intermittent corticosteroid ; etc . ) exclude . Women liver enzymes , alkaline phosphatase , bilirubin &gt; 1.5 time upper limit normal ( confirmed repeat ) exclude , exception mild bilirubin elevation accept set know Gilbert 's syndrome . Abnormal sodium potassium concentration ( confirm repeat ) ; bicarbonate concentration &lt; 20 &gt; 30 ( confirm repeat ) Women abnormal renal function ( i.e. , serum creatinine &gt; 1.4 ) exclude ( confirmed repeat ) Pregnant breastfeed woman exclude . A history allergy progesterone estradiol constitute ground exclusion . Women BMI great equal 40 kg/m2 . Virilization A total testosterone &gt; 150 ng/dl woman PCOS ( suggest possibility virilize neoplasm ) ( confirm repeat ) Elevated DHEAS ( mild elevation may see PCOS , elevation &lt; 1.5 time upper limit normal accepted PCOS ) ( confirm repeat ) Follicular 17hydroxyprogesterone &gt; 300 ng/dl , suggest possibility congenital adrenal hyperplasia ( elevated luteal phase concern possibility congenital adrenal hyperplasia , 17hydroxyprogesterone may collect follicular phase , &gt; 60 oligomenorrheic ) . NOTE : If 17hydroxyprogesterone &gt; 300 ng/dl confirm repeat testing , ACTH stimulate 17hydroxyprogesterone &lt; 1000 ng/dl require study participation . A previous diagnosis diabetes , fast glucose ≥ 126 mg/dl , hemoglobin A1c &gt; 6.5 % Abnormal TSH ( subject adequately treat hypothyroidism , reflect normal TSH value , exclude ; , new diagnosis hypothyroidism , study least delayed pending appropriate treatment ) ( confirm repeat ) Abnormal prolactin ( mild elevation may see PCOS , elevation &lt; 1.5 time upper limit normal accept group ) ( confirm repeat ) Evidence Cushing 's syndrome history physical exam Due amount blood drawn study , subject body weight &lt; 110 lb . exclude study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>PCOS</keyword>
</DOC>